Juniper Pharmaceuticals is healthcare company with core businesses consisting of its Crinone® (progesterone gel) franchise. Co. has two segments: product, which oversees the supply chain and manufacturing of Crinone®, an 8.0% progesterone bioadhesive vaginal gel designed for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency; and service, which includes pharmaceutical development, clinical trial manufacturing, and analytical and consulting services for Co.'s customers, as well as characterizing and developing pharmaceutical product candidates for Co.'s internal programs. The JNP stock yearly return is shown above.
The yearly return on the JNP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the JNP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|